INTRODUCTION
============

Alzheimer's disease (AD) is an important age-related neurodegenerative disease typically leading to progressive cognitive decline, behavioral impairments, and finally dementia ([@b4-bt-27-071]). It is assumed that the number of AD patients worldwide will quadruple from the current number of 36 million people by 2050 ([@b10-bt-27-071]). For the development of anti-AD drugs in the decade of 2002 through 2012, 244 compounds were assessed and the success rate for advancing agents for regulatory approval was only 0.4% (99.6% attrition) ([@b5-bt-27-071]). Thus, searching for effective agents for the treatment or alleviation of AD is urgently needed.

AD is characterized by the over-production of amyloid-beta (Aβ), which is regarded as one of the essential pathologic markers of AD ([@b30-bt-27-071]). Overproduction or lack of clearance of Aβ leads to an increased aggregation of Aβ, which is associated with the pathogenesis of AD ([@b11-bt-27-071]). Moreover, oxidative stress is involved in the development of AD ([@b3-bt-27-071]) and is accompanied by the activation of microglial inflammation in the presence of Aβ-mediated inflammatory response ([@b32-bt-27-071]).

Semen Ziziphi spinosae (SZS), the mature seed of *Ziziphus jujube* Mill var *spinosa* (Bunge) Hu ex H F Chou (Rhamnaceae), is widely applied in China, Japan, Korea and other oriental countries to treat insomnia and anxiety symptoms ([@b31-bt-27-071]). As one of the major active C-glycoside flavonoids in SZS, abundant literatures have demonstrated the sedative and hypnotic effects of spinosin ([@b24-bt-27-071]; [@b13-bt-27-071]; [@b27-bt-27-071]), which may be related to the regulation of postsynaptic 5-HT~1A~ receptors ([@b28-bt-27-071]). Many studies suggested that sleep is likely linked with learning and memory function ([@b7-bt-27-071]; [@b8-bt-27-071]), and spinosin was also reported to exert therapeutic potential in the treatment of cognitive impairment ([@b14-bt-27-071]; [@b15-bt-27-071]; [@b17-bt-27-071]). Even so, the mechanism of neuroprotection by spinosin is still unclear.

Intracerebroventricular (ICV) injection of Aβ was reported to cause oxidative stress and inflammation, finally resulting in apoptosis of neuronal cells ([@b20-bt-27-071]); the neurotoxicity of Aβ ensured its effectiveness in producing animal models of AD ([@b22-bt-27-071]). In the current study, we investigated whether spinosin could ameliorate cognitive impairment in a mouse model of AD induced by ICV injection of Aβ~1--42~, and further determined the underlying mechanisms - including the effect of spinosin on accommodating malondialdehyde (MDA) and brain-derived neurotrophic factor (BDNF) dysregulation, Aβ accumulation, neuronal apoptosis, and neuroinflammation.

MATERIALS AND METHODS
=====================

Animals and materials
---------------------

Male specific pathogen-free Kun-Ming mice (35--40 g) were provided by the Experimental Animal Center of Shenyang Pharmaceutical University (Shenyang, China). All the studies were performed in compliance with the Guideline for Animal Experimentation and the protocol was subject to approval by the Animal Ethics Committee of Shenyang Pharmaceutical University. All animals were housed under conventional conditions with appropriate temperature (22 ± 0.5°C), humidity (50--60%) control and a 12/12 h light/dark cycle with free access to food and water.

Spinosin (purity\>99.0%) was provided by the National Institutes for Food and Drug Control of Pharmaceutical and Biological Products (Shenyang, China) and was suspended in physiological saline solution at concentrations of 0.2 and 2 µg/µl. Recombinant human Aβ~1--42~ (Sigma-Aldrich, St Louis, MO, USA) was dissolved and diluted in physiological saline to a stock concentration of 1.0 mg/mL, which was then sealed and incubated for 120 h at 37°C to allow the peptide to aggregate ([@b18-bt-27-071]). Commercial kits for detection of MDA, B-cell lymphoma-2 (Bcl-2), BNDF, interleukin-6 (IL-6) and Aβ~1--42~ were purchased from Nanjing Jiancheng Bio engineering Institute (Nanjing, China).

Treatment and experimental design
---------------------------------

Mice were randomly divided into the following 4 groups (n=10 in each group): (I) control; (II) Aβ~1--42~; (III) Aβ~1--42~+10 µg/kg spinosin; (IV) Aβ~1--42~+100 µg/kg spinosin. Each mouse in groups II-IV was anesthetized with intraperitoneal injection of chloral hydrate (4 g/kg), and 3 µL Aβ~1--42~ was injected into left hippocampus under the stereotaxic apparatus (AP: −0.5 mm; ML: −1.1 mm; DV: −3.0 mm). Aβ~1--42~ injection was performed over 3 min, and the needle was still in place for an additional 2 min before retracting. Then, animals were implanted with cannula (8.0 mm) located 5 mm above the right ventricle (AP: −0.2 mm; ML: −1.0 mm; DV: −3.0 mm). The cannula was fixed to the skull with dental cement. Mice were given ICV injection of spinosin (10 and 100 µg/kg) daily for 7 days after surgery. The timeline for animal experiments was provided in [Fig. 1A](#f1-bt-27-071){ref-type="fig"}.

Behavioral tests
----------------

**Spontaneous locomotor activity:** The spontaneous locomotor activity of mice was measured with a Multi-autonomous Activity Instrument (Huaibei Zhenghua Bioscience Technology Limited Company, Anhui, China) consisting nine chambers (25 cm diameter×13 cm height) using a video-recorded analytical system (Shanghai Jiliang Software Technology Co. Ltd., Shanghai, China). The locomotor activity of each animal was determined by measuring the total distance of movements over a 5-min period.

**Morris water maze test:** Morris maze test was conducted according to the procedure established by Morris with slight modifications ([@b19-bt-27-071]). The Morris water maze is a dark circular pool, 90 cm in diameter and 45 cm in height. It was filled with dark water (25--27°C) to a depth of 40 cm and the black platform (8 cm in diameter and 10 cm in height) was then placed in the same quadrant (Q4) on every trial with 1 cm below the water so that it was a featureless inner surface. On the first day of Morris maze test, mice were trained for two trials with a trial interval of 10 min to find the hidden escape platform. From the second day, mice received four trials per day for 4 consecutive days. They were randomly placed in the different quadrant and were allowed to swim for 90 s to seek the hidden platform. If the mice found the platform within 90 s and remained on it for at least 3 s, then the track was terminated. If the mice failed to find the platform within 90 s, the mice were guided to the platform and were allowed to stay on it for 15 s. On the 6^th^ day, the platform was removed and the spatial probe test was given by allowing the mice to swim freely for 90 s. The time spent by the animal in the target quadrant was evaluated ([@b18-bt-27-071]).

Biochemical analyses
--------------------

Mice were deeply anesthetized after behavioral tests, the cerebral cortex and hippocampus of 6 mice in each group were dissected out and immediately stored at −80˚C. For biochemical analysis, the cerebral cortex and the hippocampus tissue were homogenized in ice-cold saline and centrifuged at 2000 rpm for 10 min to collect the supernatant. Levels of MDA were measured by the thiobarbituric acid reaction method at a wavelength of 532 nm according to manufacturer's instruction. Bcl-2, BNDF, IL-6 and Aβ~1--42~ in brain tissues were assessed by commercial sandwich enzyme-linked immunosorbent assay (ELISA) kits. In brief, protein samples from brain tissues and biotinylated antibodies targeting Bcl-2, BNDF, IL-6 or Aβ~1--42~ were added to microwells pre-coated with corresponding nonlabled antibodies. After incubation, streptavidin-HRP was added to bind to biotinylated antibodies. Following incubation with 3,3′,5,5′-tetramethyl-benzidine substrate, stop solution was added and absorbance at 450 nm (OD~450~) of each sample was recorded by a microplate reader (SpectraMax M2, Molecular Devices, Sunnyvale, CA, USA).

Histopathological examination
-----------------------------

Four mice in each group were perfused transcardially with saline followed by 4% paraformaldehyde (PFA) in phosphate buffer saline (0.1 mol/L PBS, pH 7.2) after anesthesia. The entire brains were postfixed in 4% paraformaldehyde (PFA) solution for 48 h, and then transferred to 30% sucrose in 0.1 mol/l PBS (pH 7.4) for at least 16 h until sectioning. Serial (neighboring) sections of 10 µm thickness were sectioned and stained with hematoxylin and eosin (H&E) staining ([@b1-bt-27-071]).

Statistical analyses
--------------------

Results are expressed as mean ± SD. The significances among different groups were determined using SPSS 19.0 (IBM Corp., New York, NY) where statistical significance were assessed by one-way analysis of variance (ANOVA) followed by Tukey's multiple comparison test, *p*\<0.05 was considered statistically significant.

RESULTS
=======

The spontaneous locomotor activity of mice
------------------------------------------

The influence of surgery and ICV administration of Aβ~1--42~ or spinosin on spontaneous locomotor activity of the mice was investigated. As shown in [Fig. 1B](#f1-bt-27-071){ref-type="fig"}, there was no significant difference in the spontaneous locomotor activity indicated by exploratory behavior among different groups after Aβ~1--42~ or spinosin treatment (*p*\>0.05), which suggested that surgeries or ICV injection of Aβ~1--42~ or spinosin did not have impact on locomotive activity of mice.

Spinosin improved Aβ~1--42~-induced cognitive impairment in the Morris water maze test
--------------------------------------------------------------------------------------

For the long-term memory evaluated by Morris maze test, mice with Aβ~1--42~ injection spent longer time searching for the hidden platform (latency time) than the control group during the five days training sessions. On the other hand, mice treated with spinosin (10, 100 µg/kg) after Aβ~1--42~ injection showed an improved learning and memory performance as compared to mice in model group only received Aβ~1--42~ injection ([Fig. 2A](#f2-bt-27-071){ref-type="fig"}). Accordantly, the time spending in the target quadrant in Aβ~1--42~ group was lower than those in control group in the probe trial on the 6^th^ day of the test (*p*\<0.01), while the treatment of high dose of spinosin (100 µg/kg) significantly restored the time of mice spending in the target quadrant (*p*\<0.01) ([Fig. 2B, 2C](#f2-bt-27-071){ref-type="fig"}).

Spinosin decreased the level of MDA in hippocampus of mice with Aβ~1--42~ injection
-----------------------------------------------------------------------------------

Oxidative stress was evaluated by analyzing the level of MDA in hippocampus of mice. Compared with the control group, Aβ~1--42~ injected mice in model group showed a significant elevation of hippocampus level of MDA (*p*\<0.01). After 5 days treatment with spinosin (10, 100 µg/kg), the MDA content was significantly reduced in the mice treated with both low and high doses of spinosin compared to model group ([Fig. 3A](#f3-bt-27-071){ref-type="fig"}).

Spinosin inhibited Aβ~1--42~ accumulation in the hippocampus of mice with Aβ~1--42~ injection
---------------------------------------------------------------------------------------------

The Aβ~1--42~ levels in hippocampus homogenate were evaluated, and the results showed that ICV injection of Aβ~1--42~ significantly increased the Aβ~1--42~ level in the hippocampus of mice in model group (*p*\<0.01). Compared with model group, the levels of Aβ~1--42~ were significantly decreased in the spinosin (10, 100 µg/kg) treatment groups (*p*\<0.01) ([Fig. 3B](#f3-bt-27-071){ref-type="fig"}).

Spinosin restored the level of BDNF in the hippocampus and cerebral cortex of mice with Aβ~1--42~ injection
-----------------------------------------------------------------------------------------------------------

The level of BDNF was determined in the hippocampus and cerebral cortex of mice by ELISA. As shown in [Fig. 4](#f4-bt-27-071){ref-type="fig"}, the level of BDNF in both hippocampus and cortex of Aβ~1--42~ treated mice was lower than that of control mice (*p*\<0.01), however, 100 µg/kg spinosin treatment significantly reversed BDNF level in both hippocampus and cortex (*p*\<0.01), while ICV injection of low dose of spinosin (10 µg/kg) only increased BDNF expression in the cortex (*p*\<0.01).

Spinosin reversed the level of Bcl-2 in the hippocampus and cerebral cortex of mice with Aβ~1--42~ injection
------------------------------------------------------------------------------------------------------------

The anti-apoptotic effect of spinosin level of Bcl-2 was examined by ELISA. Compared with control group, a significant decrease in protein expression level of Bcl-2 was found in the hippocampus and cerebral cortex of the mice in model group with Aβ~1--42~ treatment (*p*\<0.01). However, Bcl-2 was up-regulated significantly in both hippocampus and cerebral cortex following high dose rather than low dose of spinosin treatment compared with model group ([Fig. 5](#f5-bt-27-071){ref-type="fig"}), the results indicated that 100 µg/kg spinosin treatment could increase anti-apoptotic molecules level in the hippocampus and cerebral cortex area of Aβ~1--42~ injected mice.

Spinosin decreased the level of IL-6 in the hippocampus of mice with Aβ~1--42~ injection
----------------------------------------------------------------------------------------

To confirm the effect of spinosin on inflammatory response, the level of IL-6 in different groups was examined. IL-6 level in hippocampus was significantly higher in Aβ~1--42~ injected mice than control mice (*p*\<0.01), whereas IL-6 level was significantly decreased with spinosin (100 µg/kg) treatment (*p*\<0.01). However, no difference was found among different groups for the level of IL-6 in the cerebral cortex ([Fig. 6](#f6-bt-27-071){ref-type="fig"}).

Histopathology findings
-----------------------

In the control group, the neurons in CA1 region of hippo-campus exhibited clear nuclei and intact neuronal bodies, while swollen and dispersed neuronal bodies were found in hippocampus of Aβ~1--42~ injected mice. After low or high dose spinosin treatment, the morphological aspects of neurons were recovered significantly compared with the model group ([Fig. 7](#f7-bt-27-071){ref-type="fig"}).

DISCUSSION
==========

AD is characterized by cognitive impairment and neurodegeneration ([@b6-bt-27-071]), and Aβ peptide deposition in the brain has been recognized as a major event during the neuropathogenesis of AD ([@b12-bt-27-071]). Oral administration of spinosin was shown to improve memory in Aβ- or scopolamine-treated and normal naïve mice with cognitive dysfunction by inhibiting the 5-hydroxytriptamine 1A (5-HT~1A~) receptor, increasing choline acetyltransferase expression, reducing the number of glial cell, up-regulating adult hippocampal neurogenesis, and activating the ERK-CREB-BDNF signaling pathway ([@b14-bt-27-071]; [@b15-bt-27-071]; [@b17-bt-27-071]). In our study, spinosin was directly administrated into the brains of Aβ~1--42~ injected mice to avoid the possible metabolic effect after oral administration, and the other potential targets of spinosin for the treatment of AD were identified.

Morris water maze test was conducted to confirm the effectiveness of spinosin in control of cognitive impairment of mice with AD induced by Aβ~1--42~. The ICV administration of spinosin was shown to improve cognitive deficits in Aβ~1--42~ injected mice as evidenced by shorter escape latency and increased time spent in the target quadrant ([Fig. 2](#f2-bt-27-071){ref-type="fig"}). The results in the behavioral task indicated a neuroprotective effect of spinosin in the brain. In addition, the spontaneous locomotor activity reflected by exploratory behavior was not affected by Aβ~1--42~ or spinosin injection ([Fig. 1](#f1-bt-27-071){ref-type="fig"}).

Pathological conditions of AD are evidenced to link with oxidative stress, and the level of lipid peroxidation is considered as an important factor in AD ([@b9-bt-27-071]). The level of MDA, a marker of lipid peroxidation index, was evaluated in hippocampus rather than cortex since a high level of MDA is induced in hippocampus after ICV injection of Aβ~1--42~ ([@b33-bt-27-071]; [@b29-bt-27-071]). Our results showed that spinosin significantly attenuated the up-regulation of MDA in hippocampus induced by ICV injection of Aβ~1--42~. The evidence indicated that cognitive impairments improved by spinosin might be associated with its anti-oxidative effects ([Fig. 3A](#f3-bt-27-071){ref-type="fig"}).

As the increase of Aβ~1--42~ was considered as an index of neurotoxicity ([@b23-bt-27-071]), and the accumulation of deposits of Aβ is one of the classical neuropathological hall-marks ([@b16-bt-27-071]). The level of Aβ~1--42~ in hippocampus, the region received Aβ~1--42~ injection, was evaluated in the current study. Our study showed that ICV injection of Aβ~1--42~ significantly increased Aβ~1--42~ level in the hippocampus of mice in model group, while spinosin significantly decreased the Aβ~1--42~ level compared with model mice. These results indicated a potential improving effect of spinosin in AD via inhibition of Aβ~1--42~ accumulation ([Fig. 3B](#f3-bt-27-071){ref-type="fig"}).

The reports of association of neuroinflammation with AD pathology have led to increased interest in pursuing anti-inflammatory therapy for AD ([@b26-bt-27-071]). [@b25-bt-27-071] compared plasma concentrations of IL-6, IL-12, IFN-7, and IFN-γ in AD patients with control subjects, and IL-6 was found to be selectively elevated in AD patients. Our results showed an increased level of IL-6 in hippocampus of mice after Aβ~1--42~ injection, while the administration of spinosin decreased IL-6 level in the hippocampus ([Fig. 6](#f6-bt-27-071){ref-type="fig"}). Accordantly, [@b15-bt-27-071] reported an anti-inflammatory activity of spinosin by reducing the number of activated microglia and astrocytes in mice with Aβ~1--42~ injection. Thus, the anti-amnesic activity of spinosin was, in part, mediated by inhibiting inflammation.

BDNF, a key molecule in the maintenance of synaptic plasticity and memory storage in the hippocampus, has been shown to protect neurons from a variety of brain diseases ([@b21-bt-27-071]). Additionally, the neuroprotection by BDNF is partly mediated by the anti-apoptotic effect through the up-regulation of Bcl-2 ([@b2-bt-27-071]). In our study, spinosin was found to exert anti-apoptotic effect through the regulation of Bcl-2 ([Fig. 5](#f5-bt-27-071){ref-type="fig"}), and the results also demonstrated a neuroprotective effect of spinosin associated with the upregulation of BDNF in both hippocampus and cortex ([Fig. 4](#f4-bt-27-071){ref-type="fig"}), which is consistent with a previous study showing the activation of ERK-CREB-BDNF signaling pathway in the hippocampus after spinosin stimulation ([@b17-bt-27-071]). Therefore, spinosin might protect the neurons by regulating the expression of BDNF as its potential target.

In conclusion, in addition to previously reported targets of spinosin, neuroprotective effects of spinosin were found through the regulation of oxidative stress, Aβ~1--42~ accumulation, as well as apoptotic program in brain. These findings suggest that spinosin may represent a potential therapeutic agent to improve cognitive function in patients with AD through the regulation of multi-targets.
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![Schematic representation of the experimental design (A), and locomotor activity of mice in each group (B). Values are means ± SD (n=10).](bt-27-071f1){#f1-bt-27-071}

![Effects of spinosin on escape latency in the training sessions (A), and search strategy (B) and swimming time in target quadrant in probe trail sessions (C) of the Morris water maze test. Values are means ± SD (n=10). ^\#^*p*\<0.05 and ^\#\#^*p*\<0.01 compared with control group; ^\*\*^*p*\<0.01 compared with Aβ~1--42~ group.](bt-27-071f2){#f2-bt-27-071}

![Effect of spinosin on MDA and Aβ~1--42~ levels in the hippocampus of Aβ~1--42~ injected mice. Values are mean ± SD (n=6). ^\#\#^*p*\< 0.01 compared with control group; ^\*^*p*\<0.05 and ^\*\*^*p*\<0.01 compared with Aβ~1--42~ group.](bt-27-071f3){#f3-bt-27-071}

![Effect of spinosin on the protein expression levels of BNDF in hippocampus (A) and cortex (B) of Aβ~1--42~ injected mice. Values are mean ± SD (n=6). ^\#\#^*p*\<0.01 compared with control group; ^\*\*^*p*\<0.01 compared with Aβ~1--42~ group.](bt-27-071f4){#f4-bt-27-071}

![Effect of spinosin on the protein expression levels of Bcl-2 in hippocampus (A) and cortex (B) of Aβ~1--42~ injected mice. Values are mean ± SEM (n=6). ^\#\#^*p*\<0.01 compared with control group; ^\*^*p*\<0.05 compared with Aβ~1--42~ group; ^\*\*^*p*\<0.01 compared with Aβ~1--42~ group.](bt-27-071f5){#f5-bt-27-071}

![Effect of spinosin on the protein level of IL-6 in hippocampus (A) and cortex (B) of Aβ~1--42~ injected mice. Values are mean ± SD (n=6). ^\#\#^*p*\<0.01 compared with control group; ^\*\*^*p*\<0.01 compared with Aβ~1--42~ group.](bt-27-071f6){#f6-bt-27-071}

![Histopathological changes of neurons in hippocampus of mice after Aβ~1--42~ injection. Representative images of neurons in hippocampal CA1 region of mice from control, Aβ~1--42~, Aβ~1--42~+10 μg/kg spinosin, and Aβ~1--42~+100 μg/kg spinosin groups. The arrows indicated neuronal degeneration of hippocampal CA1 region.](bt-27-071f7){#f7-bt-27-071}
